Chu Guang Chen

Beijing Kangpusen Biotechnology Co. Ltd. is a national high-tech enterprise founded in 2011, located in Beijing, China. The Chinese company provides consultation services for genome resources protection and evaluation, gene library construction, genetic diversity evaluation, GWAS analysis, genetic map construction, and QTL positioning. The company also offers agricultural design and breeding services, whole genome select breeding, animal and plant correction, and genetically modified breeding. The company has two major testing centers covering an area of 5,000 square meters and has introduced international leading technology platforms. The company has established advanced research and development departments and have cooperated with industry experts to provide technical guidance and support.

Insight Lifetech Co., Ltd. engages in the manufacture and sale of interventional cardiovascular diagnostic and therapy products. It offers exchange fractional flow reserve (FFR) microcatheters, cardiovascular pressure measurement (CPM) systems, intravascular ultrasound systems, and microcatheters for complex percutaneous coronary intervention (PCI). The company was founded by Xiao Yang Fu and Li Li Chen on December 11, 2015 and is headquartered in Shenzhen, China.

Vivo Capital LLC (Vivo Capital) is a venture capital firm founded in 1996 by Frank C. Kung and Edgar G. Engleman. The firm is headquartered in Palo Alto, California.

Peking University provides post-secondary education services. It offers undergraduate and graduate courses. It provides courses such as basic and applied sciences, social sciences and the humanities, sciences of medicine, management, and education. The company was founded by JiaNai Sun in 1898 and is headquartered in Beijing, China.

VISEN Pharmaceuticals operates as a biopharmaceutical company. It focuses on developing therapies and patient-centric care on endocrine diseases. The firm operates a segment which is developing and commercializing paradigm-shifting endocrine therapies in Greater China. The company was founded on November 1, 2018 and is headquartered in Shanghai, China.

VISEN Pharmaceuticals (Shanghai) Co., Ltd. is a Chinese pharmaceutical company that focuses on the development of products and technology for endocrine diseases. The company is based in Shanghai, China, and the CEO of the company is An Bang Lu. The company has developed a product called Long Pei, which is the first American FDA-approved growth hormone that can be released within a week to deliver growth hormone. VISEN Pharmaceuticals has also entered into a strategic cooperation agreement with Peking University Clinical Research Institute to carry out clinical research on thyroid dysfunction.

Hangzhou New Trials Medical Technology Co., Ltd. provides medical technology services. The company is based in Hangzhou, China.